



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/712,260	11/14/2003	Signe Thorning Mejlhede	P69290US0	8054

136 7590 02/14/2007
JACOBSON HOLMAN PLLC
400 SEVENTH STREET N.W.
SUITE 600
WASHINGTON, DC 20004

EXAMINER

HEITBRINK, JILL LYNNE

ART UNIT	PAPER NUMBER
----------	--------------

1732

SHORTENED STATUTORY PERIOD OF RESPONSE	MAIL DATE	DELIVERY MODE
3 MONTHS	02/14/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.

Office Action Summary

Application No.

10/712,260

Applicant(s)

MEJLHEDE ET AL.

Examiner

Jill L. Heitbrink

Art Unit

1732

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 27 November 2006.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-21 and 24 is/are pending in the application.
- 4a) Of the above claim(s) 11-21 is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-10 and 24 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
- Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____ |

Election/Restrictions

1. This application contains claims 11-21 drawn to an invention nonelected with traverse on May 24, 2006. A complete reply to the final rejection must include cancellation of nonelected claims or other appropriate action (37 CFR 1.144) See MPEP § 821.01.

Claim Rejections - 35 USC § 102

2. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claim Rejections - 35 USC § 103

3. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

4. Claims 1-4 and 24 are rejected under 35 U.S.C. 103(a) as being unpatentable over McFarlane Pat. No. 5,510,065 taken together with Menges et al. (How to Make Injection Mold).

5. McFarlane discloses a method for injection molding a flexible (col. 1, lines 39 and 40) catheter having a hub (formed in the upper portion of the cavity adjacent the

Art Unit: 1732

proximal end 25) and a tube-shaped part (formed below the hub) as shown by the cavity shape in Fig. 1. The molten polymer is feed into a mold having a core 22 which has a cylindrical part (shown in the elongated portion of the cavity in Fig. 1) and a cone-shaped part (shown above the cylindrical part of core 22). The core is removed from the catheter when the polymer is sufficiently cured and the catheter is removed from the mold when the polymer is sufficiently cured (col. 12, lines 1 and 2). The catheter is cured to its final state in the mold since McFarlane describes the product being solidified when removed (col. 12, lines 1 and 2). The molten polymer is supplied to the mold via at least two inlets (injection ports 60). Menges teaches providing little taper of a core to reduce the friction forces when removing the core, see middle of page 405, and the "selection of cores with the greatest permissible taper", see bottom of page 405. It would have been obvious to a person of ordinary skill in the art to provide a slight draft angle on the core in McFarlane since any draft would reduce the friction forces when removing the core.

6. Claims 1, 2, 6, 7, 8 and 10 are rejected under 35 U.S.C. 103(a) as being unpatentable over Glocker et al. WO 90/00960 taken together with Menges et al. (How to Make Injection Mold).

7. Glocker discloses a method of producing soft needle catheters on core with a sleeve to assist removal as stated on page 3 of applicant's specification. Glocker discloses a method for injection molding (page 1, line 2). The core 2 is shown to have a cone shape in one mold half and a cylindrical shape in the other mold half, see Fig. 1. The mold separates perpendicular to the tube-shaped part at or just below the hub as

Art Unit: 1732

shown in Fig. 1. The molten polymer is fed into a region of the hub or cone shape so that the injected polymer will move the sleeve 3 during filling of the cavity. The core is removed from the catheter when the polymer is sufficiently cured and the catheter is removed from the mold when the polymer is sufficiently cured (page 9, last paragraph). The catheter is cured to its final state in the mold (page 10, last paragraph). Glocker (page 5, first paragraph) discloses the molding of similar materials including copolymers of polypropylene. Menges teaches providing little taper of a core to reduce the friction forces when removing the core, see middle of page 405, and the "selection of cores with the greatest permissible taper", see bottom of page 405. It would have been obvious to a person of ordinary skill in the art to provide a slight draft angle on the core in Glocker since any draft would reduce the friction forces when removing the core.

8. Claims 1, 2, 7 and 8 are rejected under 35 U.S.C. 102(b) as anticipated by or, in the alternative, under 35 U.S.C. 103(a) as obvious over Jeffs Pat. No. 5,032,343.

9. Jeffs discloses a method for injection molding a flexible micro pipette having a hub (end portion 22) and a tube-shaped part (64) as shown by the cavity shape in Fig.

6. The molten polymer is injection molded using a core 80 which has a cylindrical part (92) and a cone-shaped part (88). The core is removed from the pipette when the polymer is sufficiently cured and the pipette is removed from the mold when the polymer is sufficiently cured since the pipette is used with the injection mold removed. The pipette is cured to its final state in the mold since Jeffs describes the product being used in the shape molded by the injection molding. The product molded being a catheter rather than a micro pipette does not limit the process being claimed since the

Art Unit: 1732

dimensions are similar and the use of the product does not limit the method of producing the product. However, the use of the injection molding process to produce a catheter of similar dimensions and flexibility would have been obvious to a person of ordinary skill in the art in view of the article similarities. The injected material is polypropylene (col. 6, line 4).

10. Claims 5-10 are rejected under 35 U.S.C. 103(a) as being unpatentable over anyone of Jeffs Pat. No. 5,032,343, or either McFarlane Pat. No. 5,510,065 or Glocker et al. WO 90/00960 taken together with Menges et al. (How to Make Injection Mold), as applied to claim 1 above, and further in view of Goral et al. Pat. No. 6,630,086.

11. Goral (col. 9, lines 61-62) teach that the mold halves can be mated longitudinally or vertically. It would have been obvious to a person of ordinary skill in the art to separate the mold along the axis or perpendicular to the tube in any of the primary references since these are known alternatives in the art of molding catheters.

12. Goral teaches the selection of materials for the hub and tube equivalent to the in claims 7, 8 and 9. The process in Goral is gas assist injection molding rather than injection molding with a core. It would have been obvious to a person of ordinary skill in the art to use the material of Goral in the injection molding process of the primary reference since these material are known to be injection moldable and are known to be desired in medical catheters.

Response to Arguments

13. Applicant's arguments filed Nov. 27, 2006 have been fully considered but they are not persuasive.

14. The rejection under 112 based on the trademarks has been removed.

15. Menges et al. has been cited for teaching the providing of a draft on the core to reduce the release forces needed for ejection for the part for the core.

16. Applicant argues that the portion 24 of Jeffs is not flexible. However, the claims do not require the entire tube-shaped part to be flexible. A portion of the tube shaped part such as the cylindrical part being flexible would make the tube-shaped part flexible.

17. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire **THREE MONTHS** from the mailing date of this action. In the event a first reply is filed within **TWO MONTHS** of the mailing date of this final action and the advisory action is not mailed until after the end of the **THREE-MONTH** shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of


Art Unit: 1732

the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jill L. Heitbrink whose telephone number is (571) 272-1199. The examiner can normally be reached on Monday-Friday 9 am -2 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Johnson can be reached on (571) 272-1176. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.


Jill L. Heitbrink
Primary Examiner
Art Unit 1732